Reuters
29 May 2026, 16:44 UTC · 22w ago
Verdict
Headline leans bullish. We score MNKD +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
More positive than 88% of ticker scores this week
Search tags
What the story claims
1 claim · scored −1 bearish … +1 bullish
The FDA has approved the expanded use of MannKind's inhaled rapid-acting insulin for patients under 18 years of age.
More positive than 92% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 88% of ticker scores this week
FDA approval for expanded use of its inhaled insulin in children provides a significant growth opportunity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1h ago
−4.0%
Price is moving against the score
$3.50 vs $3.64 close before publication (May 28) · not market-adjusted
MNKD chart →
